ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag fda disease medicine biotech pharma

Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Make Mine Rare
Megan Scudellari | Aug 1, 2011 | 7 min read
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Rachael Moeller Gorman | Apr 1, 2021 | 10+ min read
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
type 1 diabetes
Biotechs Race to Develop Stem Cell Treatments for Diabetes
Eric Bender | Jul 15, 2019 | 8 min read
Insulin-producing cells grown in the lab could offer a functional cure for the disease.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
The Vaginal Microbiome is Finally Getting Recognized
Hannah Thomasy, PhD, Drug Discovery News | Sep 25, 2023 | 10+ min read
Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women's health.
The Little Cell That Could
Megan Scudellari | Jul 1, 2012 | 7 min read
Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

Run a Search

ADVERTISEMENT